Citigroup Maintains Buy on Cytokinetics, Raises Price Target to $105
Benzinga Newsdesk 21 minutes ago
Analyst RatingsNewsPrice Target
Citigroup analyst Eric Joseph maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $99 to $105.
Citigroup analyst Eric Joseph maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $99 to $105.